IO Biotech Phase 3 trial IDMC recommends continuation; PFS endpoint expected H1 2025

IO Biotech, Inc.

IDMC recommends Phase 3 trial of IO102-IO103 + pembrolizumab continue without modifications after interim analysis.
Interim ORR analysis did not meet pre-specified high statistical bar (p≤0.005); most alpha preserved for PFS.
Primary endpoint PFS event-driven at 226 events; trial 89% powered to detect 35% risk reduction; projected H1 2025.
No new safety signals observed; 407 patients enrolled across 100+ centers in US, EU, Australia, and elsewhere.
Phase 2 basket trial data for NSCLC and SCCHN accepted for presentations at ESMO and other fall meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.